AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33115269 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diets (LCDs)
Number of subjects: 2226
Study 33115269 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2226
Study 33115374 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg amiselimod
Number of subjects: 17
Study 33115374 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg amiselimod
Number of subjects: 17
Study 33115374 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg and 0.4 mg amiselimod
Number of subjects: 17
Study 33115374 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiselimod
Number of subjects: 17
Study 33115382 — intervention group
Group type: EXPERIMENTAL
Intervention: EDAS plus intensive medical management (IMM)
Number of subjects: 52
Study 33115815 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus, Letrozole, and Trastuzumab
Number of subjects: 32
Study 33115822 — intervention group
Group type: EXPERIMENTAL
Intervention: Late pregnancy (LP)
Number of subjects: 8
Study 33115822 — intervention group
Group type: EXPERIMENTAL
Intervention: Early post partum (EPP)
Number of subjects: 8
Study 33115822 — intervention group
Group type: EXPERIMENTAL
Intervention: Late post partum (LPP)
Number of subjects: 8
Study 33115826 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of plasma lipids to traditional risk factors
Number of subjects: 0
Study 33115891 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest and thumb ECG system Coala Heart Monitor, monitored two times per day for 28 days
Number of subjects: 100
Study 33115902 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based questionnaires assessing eating and physical activity behaviours, personal characteristics, and global health status.
Number of subjects: 20000
Study 33115916 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous, deuterated 25(OH)D administration
Number of subjects: 100
Study 33116195 — intervention group
Group type: EXPERIMENTAL
Intervention: GWI related chronic pain group
Number of subjects: 20
Study 33116195 — intervention group
Group type: COMPARATOR
Intervention: Military controls without GWI related diffuse body pain
Number of subjects: 20
Study 33116464 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI (Body Mass Index)
Number of subjects: 1644
Study 33116464 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 1644
Study 33116533 — intervention group
Group type: EXPERIMENTAL
Intervention: Different intervention groups for MDD subtypes (melancholic, atypical, anxious)
Number of subjects: 750
Study 33116698 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0
Study 33116698 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study 33117015 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Music Therapy (IMT)
Number of subjects: 133
Study 33117015 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Listening (PL)
Number of subjects: 133
Study 33117015 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 133
Study 33117256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sole stimulation (20 min of IAMZS)
Number of subjects: 10
Study 33117256 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IAMZS (20 min) and medication
Number of subjects: 10
Study 33117256 — intervention group
Group type: COMPARATOR
Intervention: Sole medication
Number of subjects: 10
Study 33117281 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Muscle Mass
Number of subjects: 227
Study 33117281 — intervention group
Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 227
Study 33117454 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily for one week
Number of subjects: 8
Study 33117454 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal glucose tolerance, N=7)
Number of subjects: 8
Study 33117558 — intervention group
Group type: EXPERIMENTAL
Intervention: VOLITION intervention (half-day training workshop for GPs in shared decision-making and a leaflet for patients)
Number of subjects: 180
Study 33117558 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without the VOLITION intervention)
Number of subjects: 180
Study 33117895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy combined with music therapy (10 therapy sessions and related homework)
Number of subjects: 43
Study 33117895 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 43
Study 33117961 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation; details on dosage and duration not available.
Number of subjects: 0
Study 33118017 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-incision and intermuscular (IM) technique
Number of subjects: 213
Study 33118017 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermuscular (IM) technique
Number of subjects: 213
Study 33118017 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermuscular plus two-incision technique
Number of subjects: 213
Study 33118017 — intervention group
Group type: EXPERIMENTAL
Intervention: PRAETORIAN low-risk patients
Number of subjects: 213
Study 33118017 — intervention group
Group type: EXPERIMENTAL
Intervention: PRAETORIAN score
Number of subjects: 213
Study 33118101 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of anastomotic leakage after elective colorectal surgery
Number of subjects: 76
Study 33118160 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet (0.5 to 0.6 g/kg/day)
Number of subjects: 2996
Study 33118160 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet (≥ 0.8 g/kg/day)
Number of subjects: 2996
Study 33118160 — intervention group
Group type: COMPARATOR
Intervention: Very low protein diet (0.3 to 0.4 g/kg/day)
Number of subjects: 2996
Study 33118199 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemangiol (propranolol)
Number of subjects: 94
Study 33118951 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring-based mHealth intervention
Number of subjects: 28
Study 33118955 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based SDM training program that included prenatal screening
Number of subjects: 40
Study 33118955 — intervention group
Group type: COMPARATOR
Intervention: Web-based training program focusing on prenatal screening alone
Number of subjects: 40
Study 33118959 — intervention group
Group type: EXPERIMENTAL
Intervention: selfBACK app in addition to usual care
Number of subjects: 0
Study 33118959 — intervention group
Group type: COMPARATOR
Intervention: usual care alone
Number of subjects: 0
Study 33119476 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (PARP inhibitor)
Number of subjects: 54
Study 33119478 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal radioimmunotherapy (RIT) with anti-B7H3 murine monoclonal antibody
Number of subjects: 52
Study 33119479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib plus azacitidine
Number of subjects: 23
Study 33119664 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil extracellular trap components (dsDNA, MPO-DNA, CitH3)
Number of subjects: 61
Study 33119792 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with significant CHD in the 'Monitor' range (cut-off scores ≤ -1SD)
Number of subjects: 210
Study 33119792 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with significant CHD in the 'Refer' range (cut-off scores ≤ -2SD)
Number of subjects: 210
Study 33119792 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall NDD rate in children with significant CHD
Number of subjects: 210
Study 33119792 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of non-cardiac disease in children with NDD
Number of subjects: 210
Study 33119792 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with NDD who had no developmental follow-up
Number of subjects: 210
Study 33121236 — intervention group
Group type: EXPERIMENTAL
Intervention: Danicopan monotherapy (100-200 mg thrice daily)
Number of subjects: 10
Study 33121535 — intervention group
Group type: EXPERIMENTAL
Intervention: GEMS-H
Number of subjects: 20
Study 33121535 — intervention group
Group type: COMPARATOR
Intervention: NoGEMS-H
Number of subjects: 20
Study 33121725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugary Drinks
Number of subjects: 0
Study 33121725 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificially-Sweetened Beverages
Number of subjects: 0
Study 33121725 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33121896 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric cycling (ECC)
Number of subjects: 35
Study 33121896 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric cycling (CON)
Number of subjects: 35
Study 33121896 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTR)
Number of subjects: 35
Study 33121904 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral calcium volume (MCV) >0 mm
Number of subjects: 0
Study 33122295 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal pancreatectomy (DP)
Number of subjects: 485
Study 33122314 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically treated group
Number of subjects: 1200
Study 33122314 — intervention group
Group type: COMPARATOR
Intervention: Conservatively treated group
Number of subjects: 1200
Study 33122336 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung EpiCheck (methylation-based plasma test) with low cut-off (LCO)
Number of subjects: 102
Study 33122336 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung EpiCheck (methylation-based plasma test) with high cut-off (HCO)
Number of subjects: 102
Study 33122336 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung EpiCheck (methylation-based plasma test)
Number of subjects: 102
Study 33122421 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned angiographic control (PAC) strategy performed with CT coronary after 6 months
Number of subjects: 550
Study 33122421 — intervention group
Group type: COMPARATOR
Intervention: Conservative symptoms and ischaemia-driven follow-up management
Number of subjects: 550
Study 33122421 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned angiographic control (PAC) strategy
Number of subjects: 550
Study 33122543 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous morphine infusions (median duration 20.5 hours) with paracetamol 4 times daily and rescue morphine for unacceptable pain (numerical rating scale ≥4)
Number of subjects: 118
Study 33122578 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR-TKIs as adjuvant therapy or neoadjuvant therapy
Number of subjects: 0
Study 33122578 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of MET inhibitors to EGFR-TKIs
Number of subjects: 0
Study 33122578 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel compounds targeting EGFR exon 20 insertion (EGFR20ins)
Number of subjects: 0
Study 33122578 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line osimertinib and adjuvant osimertinib
Number of subjects: 0
Study 33122713 — intervention group
Group type: EXPERIMENTAL
Intervention: Male VIPs
Number of subjects: 7555
Study 33122898 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium/Olodaterol
Number of subjects: 0
Study 33122898 — intervention group
Group type: COMPARATOR
Intervention: Any Triple Combination Therapy
Number of subjects: 0
Study 33123048 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced Environmental Stimulation Therapy (REST)
Number of subjects: 0
Study 33123159 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptively transferred virus-specific T-cells (VSTs) targeting HPIV3
Number of subjects: 10
Study 33123384 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatocyte matrix implant
Number of subjects: 11
Study 33123725 — intervention group
Group type: EXPERIMENTAL
Intervention: Autistic children
Number of subjects: 67
Study 33123725 — intervention group
Group type: COMPARATOR
Intervention: Typically developing children
Number of subjects: 67
Study 33124005 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin administered via nebulization at dose levels ranging from 22-700 μg
Number of subjects: 935
Study 33124005 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin
Number of subjects: 935
Study 33124005 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin and THRX-195518
Number of subjects: 935
Study 33124006 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg once daily
Number of subjects: 65
Study 33124006 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg once daily
Number of subjects: 65
Study 33124006 — intervention group
Group type: COMPARATOR
Intervention: Etravirine
Number of subjects: 65
Study 33124006 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral drugs with known impact on lipid profile (protease inhibitors, efavirenz, cobicistat)
Number of subjects: 65
Study 33124646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 0
Study 33124646 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33124947 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex Decongestive Physiotherapy Applications
Number of subjects: 0
Study 33125295 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified algorithm for prevention and early treatment of bleeding, differentiation syndrome, and infection; education of oncologists about early deaths in APL; frequent communication between expert and treating physician in the first 2 weeks.
Number of subjects: 120
Study 33125309 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg and ipilimumab 3 mg/kg for four cycles, followed by nivolumab maintenance therapy for up to 2 years.
Number of subjects: 35
Study 33125416 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients with AKI (n = 304)
Number of subjects: 1
Study 33125416 — intervention group
Group type: COMPARATOR
Intervention: COVID-19-negative patients with AKI (n = 420)
Number of subjects: 1
Study 33125416 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients with AKI
Number of subjects: 1
Study 33125416 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 patients without AKI
Number of subjects: 1
Study 33125416 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 AKI patients
Number of subjects: 1
Study 33125416 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 1
Study 33125520 — intervention group
Group type: EXPERIMENTAL
Intervention: Senolytic treatment targeting senescent cells
Number of subjects: 227
Study 33125520 — intervention group
Group type: COMPARATOR
Intervention: High levels of SA-β-gal in subcutaneous adipose tissue
Number of subjects: 227
Study 33125520 — intervention group
Group type: COMPARATOR
Intervention: Bariatric surgery
Number of subjects: 227
Study 33125537 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored electronic patient-reported outcomes tool (PRO-CTCAE) in addition to standard toxicity monitoring
Number of subjects: 146
Study 33125537 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring alone
Number of subjects: 146
Study 33125909 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy (taselisib, palbociclib, AZD4547, rilotumumab plus erlotinib, talazoparib, telisotuzumab vedotin)
Number of subjects: 1864
Study 33125909 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 or anti-PD-L1 therapy (durvalumab, nivolumab plus ipilimumab)
Number of subjects: 1864
Study 33125909 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (second line therapy)
Number of subjects: 1864
Study 33125909 — intervention group
Group type: COMPARATOR
Intervention: Targeted therapy
Number of subjects: 1864
Study 33125909 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 1864
Study 33125909 — intervention group
Group type: COMPARATOR
Intervention: Anti-PD-1 or anti-PD-L1-containing therapies
Number of subjects: 1864
Study 33126339 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 at 3.6 mg/kg every 3 weeks
Number of subjects: 11
Study 33126339 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1
Number of subjects: 11
Study 33126634 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained for SNSs use
Number of subjects: 130
Study 33126634 — intervention group
Group type: COMPARATOR
Intervention: Untrained for SNSs use
Number of subjects: 130
Study 33127750 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformulated T3 (2.73 µg T3 in 300 µl for 5 consecutive days)
Number of subjects: 100
Study 33127750 — intervention group
Group type: COMPARATOR
Intervention: Control articles
Number of subjects: 100
Study 33127856 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 7061
Study 33128080 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation therapy (EST) of the lower esophageal sphincter (LES)
Number of subjects: 17
Study 33128179 — intervention group
Group type: COMPARATOR
Intervention: BiV-Late
Number of subjects: 30
Study 33128179 — intervention group
Group type: EXPERIMENTAL
Intervention: Best pacing mode
Number of subjects: 30
Study 33128179 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized AVD
Number of subjects: 30
Study 33128179 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized SyncAV
Number of subjects: 30
Study 33128179 — intervention group
Group type: EXPERIMENTAL
Intervention: Nominal SyncAV and MPP
Number of subjects: 30
Study 33128208 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (28-mg intranasal dose)
Number of subjects: 820
Study 33128208 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine (various routes: intranasal, intravenous, oral)
Number of subjects: 820
Study 33128299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib 20 mg BID
Number of subjects: 15
Study 33128299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib 40 mg BID
Number of subjects: 15
Study 33128299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib 60 mg BID
Number of subjects: 15
Study 33128299 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 15
Study 33128347 — intervention group
Group type: EXPERIMENTAL
Intervention: Avacopan 10 mg plus standard-of-care (SOC)
Number of subjects: 42
Study 33128347 — intervention group
Group type: EXPERIMENTAL
Intervention: Avacopan 30 mg plus standard-of-care (SOC)
Number of subjects: 42
Study 33128347 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) only
Number of subjects: 42
Study 33128347 — intervention group
Group type: EXPERIMENTAL
Intervention: Avacopan 30 mg plus SOC
Number of subjects: 42
Study 33128347 — intervention group
Group type: EXPERIMENTAL
Intervention: Avacopan 10 mg plus SOC
Number of subjects: 42
Study 33128785 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosponge sampling
Number of subjects: 102
Study 33128796 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-18 levels
Number of subjects: 14
Study 33128796 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-18
Number of subjects: 14
Study 33128873 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mg CH5126766 three times per week
Number of subjects: 58
Study 33128873 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.2 mg CH5126766 three times per week
Number of subjects: 58
Study 33128873 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mg CH5126766 twice per week
Number of subjects: 58
Study 33128873 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mg CH5126766 (various schedules)
Number of subjects: 58
Study 33128873 — intervention group
Group type: EXPERIMENTAL
Intervention: CH5126766
Number of subjects: 58
Study 33128903 — intervention group
Group type: COMPARATOR
Intervention: Fostemsavir (600 mg twice a day) in combination with failing regimen for 8 days, followed by fostemsavir plus optimised background therapy
Number of subjects: 371
Study 33128903 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir (600 mg twice a day) plus optimised background therapy from day 1
Number of subjects: 371
Study 33128903 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir (randomised cohort)
Number of subjects: 371
Study 33128903 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir (non-randomised cohort)
Number of subjects: 371
Study 33128903 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir
Number of subjects: 371
Study 33129352 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative MRI
Number of subjects: 24
Study 33129352 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched nodal structures
Number of subjects: 24
Study 33129352 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmatched nodal structures
Number of subjects: 24
Study 33129352 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant nodal structures
Number of subjects: 24
Study 33129355 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal OUD education for healthcare providers
Number of subjects: 0
Study 33129355 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal OUD provider education
Number of subjects: 0
Study 33129688 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapien 3 THV
Number of subjects: 200
Study 33129688 — intervention group
Group type: COMPARATOR
Intervention: No HALT
Number of subjects: 200
Study 33129688 — intervention group
Group type: EXPERIMENTAL
Intervention: HALT group
Number of subjects: 200
Study 33129688 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study
Number of subjects: 200
Study 33129735 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit plaque erosion (PE)
Number of subjects: 523
Study 33129735 — intervention group
Group type: COMPARATOR
Intervention: Culprit plaque rupture (PR)
Number of subjects: 523
Study 33130007 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe/very severe constipation
Number of subjects: 338
Study 33130007 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate constipation
Number of subjects: 338
Study 33130007 — intervention group
Group type: EXPERIMENTAL
Intervention: None/very mild/mild constipation
Number of subjects: 338
Study 33130007 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed colonic transit
Number of subjects: 338
Study 33130007 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of constipation
Number of subjects: 338
Study 33130007 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing severity of constipation
Number of subjects: 338